Rekha Chaudhary, MD
Enriched profileAdjunct Professor, Internal Medicine, College of Medicine (University of Cincinnati) · University of Cincinnati College of Medicine
Rekha Chaudhary is Adjunct Professor, Internal Medicine, College of Medicine (University of Cincinnati) at University of Cincinnati College of Medicine. OpenAlex indexes 70 publications with 1,151 citations (h-index 13); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.
Data verified 27 Oct 2026
Overview
Updated 31 Oct 2026
Rekha Chaudhary, M.D., is Adjunct Professor, Internal Medicine, College of Medicine (University of Cincinnati) at University of Cincinnati College of Medicine. The public record shows 70 publications with 1,151 citations (h-index 13), centered on Glioma Diagnosis and Treatment, Ovarian cancer diagnosis and treatment, Cancer survivorship and care. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 11 companies.
- Most recent indexed publication: 2024 · Clinical cancer research
- Top research focus: Glioma Diagnosis and Treatment
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 31 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 14.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 31 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
Sponsor: National Cancer Institute (NCI)
- Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma
Sponsor: University of Cincinnati
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Sponsor: Alliance for Clinical Trials in Oncology
Industry payments
Updated 31 Oct 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202510 payments
- Celgene CorporationProgram year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20247 payments$11,757openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
35%Factor Xa inhibitor23.3%Eliquis100%Part D<11 patientsVitamin K antagonist11.7%Warfarin Sodium100%Part D<11 patientsMetabolism & gastrointestinal
23.3%Proton pump inhibitor12.6%Pantoprazole Sodium100%Part D<11 patientsSerotonin-3 Receptor Antagonist10.7%Ondansetron Hcl100%Part D<11 patientsNervous system
17.5%Other antiepileptics17.5%Levetiracetam100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 31 Oct 2026
8 congress contributions (2012–2025) across AACR, ASCO, ASTRO per OpenAlex. The most recent:
- Animated patient’s guide to melanoma: Assessing patient understanding, shared decision-making, and health outcomes.
ASCO Annual Meeting
ASCO2025Co-author - Radiation Necrosis, Pseudoprogression, and Enhancing Radiologic Changes after Photon or Proton Chemoradiotherapy for Grade 2-3 IDHmt Gliomas
ASTRO Annual Meeting
ASTRO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 31 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Phase 0/I Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas.
Clinical cancer research
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04CNS HemangiopericytomaArticle91 citations2014
- 05
Network
Updated 31 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 31 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
med12.uc.edu/institutes/uc-neuroscience-institute/members/faculty-profile/Index/Pubs/tripatrr
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med12.uc.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 31 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Board certified
American Board of Internal Medicine (Medical Oncology); certified 2005, recertified 2015
2015verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.uc.edu ↗ - MD
Northeastern Ohio College of Medicine
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.uc.edu ↗ - Bachelor's degree
Kent State University (Integrated Life Sciences)
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.uc.edu ↗ - Board certified
American Board of Internal Medicine (Hematology and Oncology)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ucneuroscience.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucneuroscience.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Melissa Delbello, MD
University of Cincinnati College of Medicine
Alan Fleischer, MD
University of Cincinnati College of Medicine
Caleb Adler, MD
University of Cincinnati College of Medicine
Ahmad Sedaghat, MD
University of Cincinnati College of Medicine
Guy McKhann, MD
Emory University School of Medicine
Patrick Wen, MD
Dana-Farber Cancer Institute
Minesh Mehta, MD
Florida International University Herbert Wertheim College of Medicine
Timothy Cloughesy, MD
Ronald Reagan UCLA Medical Center